Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702844 · ClinicalTrials.gov registry record · Phase 2
Single Arm on the Tolerability of Weekly Nab-paclitaxel
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01702844 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 42 participants.
The verdict
NCT01702844, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)
Interventions
- DRUG Nab-Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-06-25 |
| Est. Completion | 2019-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01702844
The ClinicalTrials.gov registry entry for NCT01702844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nab-Paclitaxel is the first listed.
NCT01702844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01702844 about?
NCT01702844 is a clinical study titled "Single Arm on the Tolerability of Weekly Nab-paclitaxel". The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)
What is the current status of trial NCT01702844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2013-06-25. Estimated completion is 2019-07-12.
What interventions are being tested in trial NCT01702844?
The interventions under investigation include: Nab-Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01702844?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.